Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. - Wikidata - awgldk - TriplyDB

Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells.

Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells.

http://www.wikidata.org/entity/Q39773550

about

Hypoxia-inducible factors and the response to hypoxic stress HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy Hypoxia-induced cytotoxic drug resistance in osteosarcoma is independent of HIF-1Alpha Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB VHL deficiency augments anthracycline sensitivity of clear cell renal cell carcinomas by down-regulating ALDH2.The effect of vorinostat on the development of resistance to doxorubicin in neuroblastoma.TRIM8 anti-proliferative action against chemo-resistant renal cell carcinoma.VHL, the story of a tumour suppressor gene.The multifaceted von Hippel-Lindau tumour suppressor protein.The human melanoma side population displays molecular and functional characteristics of enriched chemoresistance and tumorigenesis.Mitochondrial dysfunction impairs tumor suppressor p53 expression/function.Reciprocal influence of the p53 and the hypoxic pathways Low expression of phosphatase and tensin homolog in clear‑cell renal cell carcinoma contributes to chemoresistance through activating the Akt/HDM2 signaling pathway.Endothelial cell HIF-1α and HIF-2α differentially regulate metastatic success RING finger protein 31 promotes p53 degradation in breast cancer cells.Noncytotoxic differentiation treatment of renal cell cancer.The VHL/HIF axis in clear cell renal carcinoma.Loss of VHL promotes progerin expression, leading to impaired p14/ARF function and suppression of p53 activity.Combined mutation of Vhl and Trp53 causes renal cysts and tumours in mice HIF isoforms in the skin differentially regulate systemic arterial pressure.Homozygous G/G variant of SNP309 in the human MDM2 gene is associated with earlier tumor onset in Caucasian female renal cell carcinoma patients.Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part II.The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma.Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions.The growing complexity of HIF-1α's role in tumorigenesis: DNA repair and beyond.The impact of hypoxia on cell death pathways.Apoptotic cell death under hypoxia.JS-K, a GST-activated nitric oxide donor prodrug, enhances chemo-sensitivity in renal carcinoma cells and prevents cardiac myocytes toxicity induced by Doxorubicin.Implications of Oxygen Homeostasis for Tumor Biology and Treatment.Hypoxia: A Double-Edged Sword in Cancer Therapy.Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways Epigenetic regulation of HIF-1α in renal cancer cells involves HIF-1α/2α binding to a reverse hypoxia-response element.A new connection between VHL and cancer threads through progerin.The apoptosis repressor with a CARD domain (ARC) gene is a direct hypoxia-inducible factor 1 target gene and promotes survival and proliferation of VHL-deficient renal cancer cells.K63-ubiquitylation of VHL by SOCS1 mediates DNA double-strand break repair.Epigenetic silencing of ASPP1 confers 5-FU resistance in clear cell renal cell carcinoma by preventing p53 activation.PI3K/AKT inhibitors in patients with refractory renal cell carcinoma: what have we learnt so far?Aqueous Extracts of Toona sinensis Leaves Inhibit Renal Carcinoma Cell Growth and Migration Through JAK2/stat3, Akt, MEK/ERK, and mTOR/HIF-2α Pathways.

P2860

Q24629323-E7B93C2C-26EF-40C3-861E-D79F18C66775 Q27025886-358F1718-E2CC-435E-9F87-7DB489A0A6EE Q27727998-D1991681-15B4-4C7D-BE04-27C8AE90EE20 Q28067724-046FD04A-9986-4D4A-B5EE-40B701A211C7 Q28533909-DE910D76-49B7-4654-A7A7-34BD162AA787 Q33656653-98536AB7-3E42-4944-B7F5-FC0201E96FFC Q33826897-C229B816-96EC-4A4E-B696-652140A77CAF Q34351080-4D14F2CA-5768-40E2-9263-3B34A52DC027 Q34365715-4D701D92-A15A-4BEC-8544-40198CDBAE5C Q34455226-8FC06C06-F271-4ED0-9956-61B3DE15E404 Q34660062-C727B020-1EB9-4C0C-BF55-8F373DDAC732 Q35009536-7DC50644-9814-42CE-BE6A-9FB187ED0C71 Q35063355-D4C1A345-7FB1-4FD8-AB1B-355AAE4E9F71 Q35065006-C1A915C8-012C-4BD9-A065-E60FCB42DE3C Q35728921-E0B2A7E3-C556-4483-A1BA-813F1B31BD00 Q35906539-ED8A30D1-7074-4A54-AF65-16BF461A0A35 Q36804413-E7A39AF0-9522-40B9-ACAC-6DD20372A8CE Q36866357-FAA5571F-C594-437C-AC81-677339A6F768 Q36872295-53526F42-D20B-438D-AE71-8C1BD0A4D3C3 Q37126195-E491B320-C2C2-4329-B12C-D2FF2A975670 Q37188593-AF428B41-DAB4-447D-BF3C-FBF86B8F422D Q37255955-1F7C5BCF-17D1-43D3-8AD7-DFA165A842D2 Q37499251-2F9E175D-D5FD-4226-B5F5-07E552FDF019 Q37882456-D0870187-75F8-4339-9EF2-0E4B476B9732 Q37884379-97508C77-6F74-4AF8-A2DC-05FA3A50F147 Q38003390-0602A2AB-BA80-4355-996D-BE0F3C320D0E Q38060522-C5623B40-8963-4A41-A834-BD2A96CDA2CE Q38091503-61A61B94-A54C-4378-ADFA-608A31269039 Q38208805-DEA3DA3B-DBBB-4DED-BFCF-E32934094873 Q38700491-48601697-3E3D-4DD3-AC06-42F5E2686549 Q38876568-35096BCC-328E-456E-9ABB-EC4AC8CEDEBD Q39002822-0A814787-F8A1-4396-8E71-AAB27BA0002B Q39077231-B363056A-C807-4168-9F06-AB6129696105 Q39490284-1BEB6D47-03C6-417E-9298-836C6B19E29D Q41827079-83C41598-5318-40DC-B7FB-D297F84BC6CA Q41908755-1E709F4E-51C0-4E96-A8B8-4CD3CA7F82D3 Q45363184-DDF03EAA-32B1-4365-88E9-AEEBE2B90FC2 Q47979679-77B45205-3B5F-4EC9-82D2-D07F18C0C042 Q52778165-39153625-934B-488E-87E1-AAEBEB53C6ED Q53114366-08FBD7C7-6719-4C9C-AF9D-AAA7734D3243

P2860

Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells.

http://www.wikidata.org/entity/Q39773550

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Suppression of hypoxia-inducib ...... ance of renal carcinoma cells.

@en

Suppression of hypoxia-inducib ...... ance of renal carcinoma cells.

@nl

type

label

Suppression of hypoxia-inducib ...... ance of renal carcinoma cells.

@en

Suppression of hypoxia-inducib ...... ance of renal carcinoma cells.

@nl

prefLabel

Suppression of hypoxia-inducib ...... ance of renal carcinoma cells.

@en

Suppression of hypoxia-inducib ...... ance of renal carcinoma cells.

@nl

P1433

Q39773550-A3BA338A-08E8-4695-9D46-B3F469475209

P1476

Q39773550-18B5AAD0-9070-42CD-8EB6-0F4F59B2AFA4

P2093

Q39773550-1E27F18D-FA7E-4C60-84A5-53E0C186299B

Q39773550-29C1D488-1C2A-4B68-8CDA-8A7FA9E8B455

Q39773550-62D31105-6BF6-423A-801F-2AAD67C28B68

Q39773550-7CB14687-9B01-48B8-909F-A5F36CD2D0B8

Q39773550-BE86FE22-5EE1-423A-9957-B42FC3173C4A

Q39773550-D666F060-2E57-490A-AF0E-37D7BEA7DE17

P2860

Q39773550-0C08689A-EB73-4A90-8707-6BDC0A1FEBFE

Q39773550-0D6F0BCE-B9DF-49F0-AB44-1061ED1F7BF1

Q39773550-0EC3DF7E-D758-438A-804A-1CB42827C05E

Q39773550-10C61F0A-436A-4ED1-B662-788D24202F83

Q39773550-184704C4-5040-4754-9D8B-B68C8B8B4FA6

Q39773550-19B4EDAF-DA33-47AA-81C7-778928E2131E

Q39773550-1B393AFE-9EEE-4E01-A5EE-743A8BF32043

Q39773550-266D6E18-BE6B-45A1-B404-B23D4DA13BE2

Q39773550-36E83FE6-C4EA-46CA-B606-C9E88D41F301

Q39773550-389DE980-EC86-49AC-A84D-C7E42BF12830

P304

Q39773550-18D5803A-469D-4C74-A388-3185DB8CEBD2

P31

Q39773550-E924EBB8-3837-411E-B97C-D179496670E2

P356

Q39773550-324F926E-6E53-4F71-BF66-C1A7ABAE7166

P407

Q39773550-FC9B0A47-FE8F-46B6-91ED-63C25EF53355

P433

Q39773550-1216A5E8-20D7-48C6-B0A5-D0B366F0FAF2

P478

Q39773550-4BB423D0-1E04-4AD6-887D-6FFE36F91182

P577

Q39773550-CCE9D6E1-F9DF-4F0F-8958-B25DD86511AC

P5875

Q39773550-DF82ECF4-D038-4F4E-A634-132DC9A170F6

P698

Q39773550-09B8875A-4331-454F-B58E-B51BED1C25C7

P921

Q39773550-C0C5EBCE-9597-4158-BA72-A35960710303

P932

Q39773550-F30BF38A-0E21-406F-ADD2-289C2593A650

P356

0008-5472.CAN-09-1770

P1433

Cancer Research

P1476

Suppression of hypoxia-inducib ...... ance of renal carcinoma cells.

@en

P2093

Andrew J Evans

http://www.w3.org/2001/XMLSchema#string

Andrew M Roberts

http://www.w3.org/2001/XMLSchema#string

David A Foster

http://www.w3.org/2001/XMLSchema#string

Ian R Watson

http://www.w3.org/2001/XMLSchema#string

Meredith S Irwin

http://www.w3.org/2001/XMLSchema#string

Michael Ohh

http://www.w3.org/2001/XMLSchema#string

P2860

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2

Mechanism of activation of protein kinase B by insulin and IGF-1

Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2

AKT/PKB signaling: navigating downstream

pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2

Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth

Molecular basis of the VHL hereditary cancer syndrome

The von Hippel-Lindau tumor suppressor gene and kidney cancer

Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein

P304

9056-9064

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-09-1770

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38096015

http://www.w3.org/2001/XMLSchema#string

P698

19920202

http://www.w3.org/2001/XMLSchema#string

P921

P932

2789194

http://www.w3.org/2001/XMLSchema#string